Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant
Articolo
Data di Pubblicazione:
2020
Citazione:
Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant / Cucchetti, Alessandro; Serenari, Matteo; Sposito, Carlo; Di Sandro, Stefano; Mosconi, Cristina; Vicentin, Ilaria; Garanzini, Enrico; Mazzaferro, Vincenzo; De Carlis, Luciano; Golfieri, Rita; Spreafico, Carlo; Vanzulli, Angelo; Buscemi, Vincenzo; Ravaioli, Matteo; Ercolani, Giorgio; Pinna, Antonio Daniele; Cescon, Matteo. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 73:2(2020), pp. 342-348. [10.1016/j.jhep.2020.03.018]
Abstract:
S AIMS: The weight of response to neo-adjuvant therapies, to select candidates with hepatocellular carcinoma (HCC) for liver transplantation (LT) at acceptable risk of recurrence, remains partially unsolved for most of post-LT prediction models. Aim of this study was to embed radiological response in the Metroticket 2.0 model for post-LT prediction of "HCC-related death" to provide more usefulness in the modern clinical scenario.
Tipologia CRIS:
Articolo su rivista
Keywords:
hepatocellular carcinoma; liver transplant; mRECIST; neo-adjuvant therapy; survival
Elenco autori:
Cucchetti, Alessandro; Serenari, Matteo; Sposito, Carlo; Di Sandro, Stefano; Mosconi, Cristina; Vicentin, Ilaria; Garanzini, Enrico; Mazzaferro, Vincenzo; De Carlis, Luciano; Golfieri, Rita; Spreafico, Carlo; Vanzulli, Angelo; Buscemi, Vincenzo; Ravaioli, Matteo; Ercolani, Giorgio; Pinna, Antonio Daniele; Cescon, Matteo
Link alla scheda completa:
Pubblicato in: